Stem Cell Agency Banks on $32 Million New Approach to Advance Research When you need money you go to the bank. But when researchers need high quality stem cells where do they go to get those? Soon they’ll be able to go to a stem cell bank set up by California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM). The governing Board of the agency voted to approve nine applications to create the cells that will go in that bank and to run it. [California Institute for Regenerative Medicine] Press Release bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology bluebird bio announced the formation of a broad, global strategic collaboration with Celgene Corporation to discover, develop and commercialize novel disease-altering gene therapies in oncology. The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor T-cells, to target and destroy cancer cells. [bluebird bio] Press Release Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments Sanofi and Transgene SA announced a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene’s therapeutic products. [Sanofi SA] Press Release Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial RNAi-based therapeutics company Benitec Biopharma Limited announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential “one-shot-cure” for Hepatitis C. [Benitec Biopharma Limited] Press Release Bone Therapeutics Awarded Manufacturing Authorization and European Approval to Produce Allogeneic Bone Cell Therapy Products BONE THERAPEUTICS announced that it has been awarded both ‘Tissue Establishment and ‘GMP’ Accreditation for the manufacturing of its ALLOB® allogeneic bone cell therapy product, being initially developed for the treatment of impaired fractures. [Bone Therapeutics SA] Press Release European Patent Office to Grant Patent for Macrocure’s CureXcell® Macrocure announced that the European Patent Office intends to grant a European patent covering Marcocure’s flagship product, CureXcell®. The patent will be officially granted under an application titled “Activate Leukocyte Composition” and will provide patent coverage for CureXcell® in Europe through March 2030. [MacroCure] Press Release St. Jude Children’s Research Hospital Announces Issuance of U.S. Patent for Genetically Modified Human Immune Cells for Cancer Therapy The United States Patent and Trademark Office awarded St. Jude Children’s Research Hospital U.S. patent number 8,399,645 for St. Jude’s invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. [St. Jude Children’s Research Hospital] Press Release NW Bio Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells Northwest Biotherapeutics (NW Bio) announced that it has been issued a key U.S. patent (#8389278) covering novel processes for manufacturing human dendritic cells. The cells produced through these processes are much more potent in their capacity to activate the immune system than those produced by the standard methods used throughout academia and industry today to produce dendritic cells. [Northwest Biotherapeutics, Inc.] Press Release Regen BioPharma Receives IND # from FDA for HemaXellerate Regen BioPharma, Inc. announced issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia. [Marketwire] Press Release Dicerna Announces Patent Issuance for Dicer Substrate siRNA Directed at the KRAS Gene, a Key Cancer Regulator Dicerna Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has issued patent claims specific to double-stranded RNAs directed against the important oncology gene target KRAS. [Dicerna Pharmaceuticals, Inc.] Press Release |